Global Statistics

All countries
Updated on September 25, 2022 3:40 pm
All countries
Updated on September 25, 2022 3:40 pm
All countries
Updated on September 25, 2022 3:40 pm

Global Statistics

All countries
Updated on September 25, 2022 3:40 pm
All countries
Updated on September 25, 2022 3:40 pm
All countries
Updated on September 25, 2022 3:40 pm
- Advertisment -

How Effective Is The J&j Covid Vaccine

Amazon Established A Foothold In Diagnostics During Covid

Study: J& J COVID-19 Vaccine 72% Effective in U.S.

There have been reports of severe allergic reactions to the mRNA vaccines. Both the Pfizer and Moderna vaccines appear, on rare occasions, to trigger anaphylaxis, a severe and potentially life-threatening reaction. People who develop anaphylaxis must be treated with epinephrine the drug in EpiPens and may need to be hospitalized to ensure their airways remain open. The CDC says people should be monitored for 15 minutes after getting a Covid-19 shot, and 30 minutes if they have a history of severe allergies. J& J recently revealed that a single case of anaphylaxis has been reported in someone who received its vaccine.

It will take time to come up with a firm estimate of how frequently this side effect occurs. The most recent data from the CDC suggest that anaphylaxis occurs at a rate of about 2.5 cases per one million doses given of the Moderna vaccine, and 4.7 cases per million doses of the Pfizer. Many of the people who have developed anaphylaxis have a history of severe allergies and some have had previous episodes of anaphylaxis.

The mRNA vaccines carry a small risk of myocarditis and pericarditis, two types of heart inflammation that are most commonly seen soon after people receive their second shots, health officials have said. Men under 40 seem to be at highest risk, particularly those aged 12 to 17. Most cases reported have been mild and resolved.

How Long Will The Johnson & Johnson Vaccine Protect You

How long the J& J and Moderna vaccines will protect against COVID-19 is currently unknown. Research suggests that the Pfizer vaccine will offer protection for 6 months, but studies are ongoing.

Earlier clinical trials of the J& J vaccine found that a single dose of the vaccine produced a strong immune response in most people. Measurements taken 71 days later found that levels of antibodies remained stable or had increased.

Overall, more research is needed to determine how long the J& J vaccine will protect against COVID-19. Its possible, but not certain, that a booster may be needed in the future.

Wouldnt A J& j Booster Take Away From Its One

Some people might still get J& Js single shot, but not follow up with a booster if it becomes available. Although its ideal for people to get the booster, for those who dont, getting one shot is still important, says Dr. Meyer, adding that it’s better to have a baseline level of protection from a one-shot vaccination than it is to be completely unvaccinated. Its better to think of boosters as a way to get the most impact.

Dr. Sude reminds people that in the world of vaccines, experts considered Johnson & Johnsons shot to be a strong vaccine from the beginning. The cutoff for FDA authorization of any COVID-19 vaccine has been 50% efficacy, she says, and all of the vaccines authorized in the U.S. surpassed that. While Johnson & Johnson has always been a very good vaccine for many people, a boosteror what we may eventually call a standard second dosewould make it a better one, she says.

Don’t Miss: Covid Test Cost Cvs

Moderna Vaccine May Produce More Than Twice The Number Of Antibodies Than The Pfizer Vaccine

A small study of 1,600 healthcare workers from a Belgian hospital showed that people who received 2 doses of the Moderna vaccine had higher antibody levels more than twice the average amount than those who received 2 doses of the Pfizer vaccine.

Antibodies are substances the immune system produces that can help the body fight infections like SARS-CoV-2, the virus that causes COVID-19. Higher antibody levels may indicate some degree of protection against COVID-19. But there are other parts of the immune response that play a role, so we dont have a full picture of what these findings mean for COVID-19 immunity.

While this study supports the Moderna vaccines effectiveness, both vaccines are still considered to be highly effective at preventing hospitalization and death from COVID-19.

  • What this means: The Moderna vaccine may lead to higher antibody levels than the Pfizer vaccine, but its unclear what this means in terms of protection. While other studies have looked at effectiveness differences against variants, these findings dont specifically link antibody levels to protection against variants of concern or transmission.

  • What this doesnt mean: One vaccine should be preferred over another. If you choose to be vaccinated, the best vaccine continues to be the one that you have access to first.

To read more about this study, click or tap here.

Moderna And Pfizer Vaccines Thought To Be Up To 86% Effective Against Hospitalization Caused By Covid

J& J Covid vaccine moderately effective, less against S ...

A different CDC report found that the Moderna and Pfizer COVID-19 vaccines are effective against hospitalization caused by COVID-19. The report used data from March to July 2021 and concluded that 2 doses of either vaccine series helped prevent hospitalization over 80% of the time.

About 1,100 people were analyzed to collect this information. Up to 3 months after vaccination, the vaccines were seen to be about 86% effective. After that up to 6 months after vaccination the vaccines were about 84% effective.

These numbers reflect hospitalizations caused by the Delta variant and previous variants. But this study only analyzed hospitalized adults, and it didnt look at the specific effects of the J& J vaccine.

  • What this means: COVID-19 vaccination lowers the risk of hospitalization from infection.

  • What this doesnt mean: We dont know how effective the J& J vaccine is at preventing hospitalization. It wasnt included in this study, but its been studied elsewhere.

To read more about this report, click or tap here.

Read Also: How Much Is Covid Test At Cvs

Some People Are Concerned That The Overall Efficacy Of The J& j Vaccine 66 Percent Globally 72 Percent In The Us Is Lower Than The 94

The way I think about these vaccine trials is to look at the worst outcomes first hospitalizations and deaths from COVID-19 because thats what got us into trouble to begin with, said Gandhi.

In the J& J trial, the placebo group had 16 hospitalizations and seven deaths from COVID-19, whereas the vaccine group had none, which means the vaccine provided 100 percent efficacy against hospitalizations and deaths.

For severe disease, which includes people who were sick enough with COVID-19 to require medical intervention but recovered without hospitalization, the efficacy was about 85 percent across the board in Brazil, South Africa and the U.S.

Including mild and moderate disease, the overall efficacy was 66 percent, but varied across the regions: 72 percent in the U.S., 64 percent in South Africa, and 61 percent in Brazil. Mild and moderate outcomes could include a range of illness, said Gandhi, and we wont know the details until the full trial results are published, but we do know that everyone recovered without medical intervention.

Admittedly, against mild to moderate disease, it didnt work as well, and I understand peoples concerns, said Gandhi.

Cars lined up at the the City College drive-through vaccination site in San Francisco.

Q: Why Did The Fda And Cdc Make The Decision To Resume Use Of The Janssen Covid

A: On April 13, 2021, the FDA and CDC recommended a pause in the use of Janssen COVID-19 Vaccine due to reports of serious adverse events of a type of blood clot in the large blood vessels in the brain called cerebral venous sinus thrombosis in combination with low levels of blood platelets . Thrombosis with thrombocytopenia is also referred to as thrombosis with thrombocytopenia syndrome.

The FDA and CDC have reviewed all of the available data, including new information since our recommendation to pause the use of the vaccine. Those data, plus the deliberations and recommendations of CDCs Advisory Committee on Immunization Practices , helped with our assessment that the known and potential benefits of Janssen COVID-19 Vaccine outweigh its known and potential risks in individuals 18 years of age and older. At this time, the available data suggest that the chance of this serious adverse event occurring is very low, but investigation into the level of potential excess risk due to vaccination is ongoing.

The Fact Sheet for Healthcare Providers Administering Vaccine has been updated to include a Warning pertaining to the risk of thrombosis with thrombocytopenia. The Fact Sheet for Recipients and Caregivers has also been updated to include information about these serious adverse events.

We will continue to closely monitor the safety of the Janssen COVID-19 Vaccine.

Don’t Miss: How Much Is Covid Test At Cvs

Healthj& j Vaccine Deemed Safe And Effective In Documents Released By Fda

The effectiveness varied when researchers tested the vaccine in other countries, where variants of the coronavirus are circulating. In Latin America, where the variant P.1 has cropped up, the vaccine was found to be 66 percent effective. In studies in South Africa, where a variant called B.1.351 is circulating, effectiveness was lower: 64 percent.

But the numbers don’t tell the whole story.

When researchers looked specifically at the vaccine’s protection against the most severe forms of illness, effectiveness shot up to 86 percent.

And it prevented 100 percent of hospitalizations and deaths related to Covid-19. No one who got the Johnson & Johnson shot was hospitalized or died of Covid-19 during the study’s follow-up period of 28 days after vaccination.

J& j Vaccine Previously Linked To Rare Cases Of Blood Clots

J& J Covid-19 vaccine 66% effective globally

The US Food and Drug Administration and CDC have said for months that the J& J vaccines known and potential benefits outweigh its known and potential risks. However, the CDC says that women younger than 50 should be made aware of the increased risk of TTS, and that there are other vaccine options available.

Thrombosis and thrombocytopenia syndrome has been linked to both the Johnson & Johnson vaccine and AstraZeneca vaccine, which is not available in the United States, but is widely used around the world and uses similar technology.

The agencies say people who receive the J& J vaccine and particularly women younger than 50 should watch for symptoms for several weeks after vaccination, including severe or persistent headaches or blurred vision shortness of breath chest pain leg swelling persistent abdominal pain or easy bruising or tiny blood spots under the skin beyond the injection site. If any of those symptoms develop, people should seek medical care immediately.

On Tuesday, the FDA said people with a history of TTS should not get the Johnson & Johnson Covid-19 vaccine.

You should not get the Janssen COVID-19 Vaccine if you had a severe allergic reaction after a previous dose of this vaccine had a severe allergic reaction to any ingredient of this vaccine had a blood clot along with a low level of platelets following Janssen COVID-19 Vaccine or following AstraZenecas COVID-19 vaccine , reads the fact sheet for vaccine recipients and caregivers.

Also Check: How Much Is Covid Test At Cvs

Number Of Doses/amounts Of Vaccine Per Dose

Both the Moderna and the Pfizer vaccines require two shots: a priming dose, followed by a booster shot. The interval between Moderna doses is 28 days for the Pfizer vaccine, its 21 days.

Each dose of Pfizers contains 30 micrograms of vaccine. Moderna went with a much larger dose of vaccine, 100 micrograms. It means the company is using a little more than three times as much vaccine per person as Pfizer is. And yet, they arent getting better results. The governments vaccine development program, formerly called Operation Warp Speed, has asked Moderna to test if it could lower the dosage of its vaccine without eroding the vaccines protection.

The J& J vaccine is, as mentioned, a single-dose vaccine. The company is also testing a two-dose regimen, with the two shots given eight weeks apart. The results from that 30,000-person trial arent expected until sometime in May.

J& J is also testing what happens to antibody responses when a person who received the single dose regimen receives a small booster shot quite a bit later, Johan Van Hoof, managing director of Janssen Vaccines revealed recently. Van Hoof didnt say how long the interval is between the single shot and the small booster, nor did he say when J& J expects results from that study.

Q: What Should Health Care Providers Look For In Evaluating Janssen Covid

A: Healthcare providers should be alert to the signs and symptoms of thrombosis with thrombocytopenia syndrome in individuals vaccinated with Janssen COVID-19 Vaccine. In individuals with suspected thrombosis with thrombocytopenia and who were vaccinated with Janssen COVID-19 Vaccine, heparin may be harmful and alternative treatments may be needed. Consultation with hematology specialists is strongly recommended.

Additional information for clinicians is available from CDC in its Health Alert Network notice, Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine.

In addition, The American Society of Hematology has information on its website relevant to the diagnosis and treatment of thrombosis with thrombocytopenia following the Janssen COVID-19 Vaccine.

Recommended Reading: How Much Is A Rapid Test At Cvs

Expect The Same Side Effects

Aside from the extremely rare blood clots discussed above, the side effects for the J& J vaccine are very similar to those for the mRNA vaccines, including injection-site pain, headache, fatigue, fever, chills and muscle aches, said Dr. Fryhofer.

With most of the side effects occurring within one to two days following vaccination, Dr. Fryhofer recommends choosing a day or two when you dont have a lot of important stuff going on, because you might not feel well.

How Effective Is The Johnson & Johnson Vaccine Against Covid


Its completely normal for viruses to mutate. When this occurs, new variants can emerge.

So far, several different variants of the novel coronavirus have been identified. Some of these have caused concern amongst public health officials. This is because the variants may be more contagious or escape the immune response.

The J& J vaccine clinical trial can give us some indication of how effective the vaccine is against these variants. This is because the trial was carried out at a time when viral variants were very common in some locations.

At the time of the trial, 95 percent of sequenced COVID-19 cases in South Africa were caused by the B.1.351 variant. The efficacy of the J& J vaccine at this location was 52 percent for mild to moderate COVID-19 and 73.1 percent for severe to critical COVID-19.

Similarly, in Brazil, 69 percent of the sequenced COVID-19 cases were caused by the P.2 lineage. The efficacy of the J& J vaccine in Brazil was 66.2 percent for mild to moderate COVID-19 and 81.9 percent for severe to critical COVID-19.

Also Check: How Long Does Cvs Rapid Test Take

How Well The Vaccine Works

  • The J& J/Janssen COVID-19 Vaccine was 66.3% effective in clinical trials at preventing laboratory-confirmed COVID-19 infection in people who received the vaccine and had no evidence of being previously infected. People had the most protection 2 weeks after getting vaccinated.
  • In the clinical trials, the vaccine had high efficacy at preventing hospitalization and death in people who did get sick. No one who got COVID-19 at least 4 weeks after receiving the J& J/Janssen COVID-19 Vaccine had to be hospitalized.
  • CDC will continue to provide updates as we learn more about how well the J& J/Janssen COVID-19 Vaccine works in real-world conditions.

The Cdc Recommends Boosters For All Adults And Allows You To Mix And Match

The CDC now recommends booster shots for all Americans ages 16 and older. People who received two doses of Pfizer’s or Moderna’s vaccine should get boosted at least six months after their second shot, the CDC advises, whereas J& J recipients can get boosted as early as two months after their first dose.

The CDC has also approved a “mix and match” approach so people can select a booster of a different vaccine type or different manufacturer than their original dose.

An funded by the US National Institutes of Health found that mix and match boosters yielded similar side effects to initial vaccine doses. More than half of the study’s 458 participants reported malaise, headaches, and muscle aches after their booster while more than 70% experienced mild arm pain.

A UK study similarly identified fatigue, headaches, and pain at the injection site as the most common side effects. The study looked at nearly 2,900 people who had received two doses of Pfizer or AstraZeneca, followed by one of seven different COVID-19 boosters. Overall, side effects from boosters were more common in people ages 30 to 69 than those ages 70 and up, the study found regardless of which vaccines the participants received.

Read Also: Cost Of Cvs Covid Test

Q: Is There Information About The Effectiveness Of Janssen Covid

A: Information is available for the United States, South Africa, and Brazil. A subgroup analysis was conducted for these countries. Following are the results of this analysis:

  • United States: the vaccine was 74.4% effective and 72% effective in preventing moderate to severe/critical COVID-19 occurring at least 14 days and 28 days after vaccination, respectively.
  • South Africa: the vaccine was 52.0% effective and 64.0% effective in preventing moderate to severe/critical COVID-19 occurring at least 14 days and 28 days after vaccination, respectively.
  • Brazil: the vaccine was 66.2% effective and 68.1% effective in preventing moderate to severe/critical COVID-19 occurring at least 14 days and 28 days after vaccination, respectively.

Use Of The Johnson & Johnson Vaccine Has Resumed After A Pause Recommended By The Fda And Cdc In Order To Study Reports Of Severe Blood Clots What Are The Risks Of This Rare Side Effect

Is The J& J COVID Vaccine Effective Against Variants? Dr. Mallika Marshall Answers Your Questions

As of May 6, 2021, 16 cases of these blood clots have been reported among a total of about 8 million people who received the J& J vaccine. The unusual condition is known as thrombosis with thrombocytopenia , or TTS, which normally occurs at a rate of about one in a million per year in the general population. Among those who have received the J& J vaccine, the rate is about two in a million. That is on par with the rate of anaphylaxis, a severe allergic reaction, that has been reported for the mRNA vaccines, about 2.5 per million.

The risk appears to be higher in younger women: 15 of the confirmed cases have been in women, and 13 of these in women ages 18 to 49. Among women ages 18 to 49, the risk of TTS after the J& J vaccine is about seven in a million.

So that does put the risk in context, in the sense that it is still extremely low, said Gandhi.

TTS also has been reported after the AstraZeneca vaccine in Europe, but its not yet clear in either case how the vaccines may be causing these blood clots. Similarities with an autoimmune condition known as heparin-induced thrombocytopenia suggests the body is producing antibodies against its own platelets.

Read Also: How Much Is Covid Test At Cvs

- Advertisment -

Hot Topics

- Advertisment -

Related Articles